Osteochondroma, a benign bone tumor, has garnered recent attention in cancer research due to its potential for malignant transformation. While typically non-cancerous, osteochondromas possess a small risk of evolving into chondrosarcomas, a type of bone cancer. Researchers are delving into the genetic and molecular mechanisms underlying this transformation, aiming to identify predictive markers and therapeutic targets. Advanced imaging techniques and molecular profiling enable early detection of malignant progression, facilitating timely intervention. Moreover, studies explore the tumor microenvironment and its role in fostering malignant transformation, offering insights into novel treatment strategies. By elucidating the complexities of osteochondroma progression, ongoing research endeavors strive to improve diagnostic accuracy, refine risk stratification, and ultimately enhance patient outcomes in the realm of bone cancer.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China